{"id":76767,"date":"2026-08-27T12:34:00","date_gmt":"2026-08-27T04:34:00","guid":{"rendered":"https:\/\/flcube.com\/?p=76767"},"modified":"2026-08-27T12:34:01","modified_gmt":"2026-08-27T04:34:01","slug":"astellas-doses-first-patient-in-phase-3-trial-of-bispecific-asp2138-for-first-line-gastric-cancer","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=76767","title":{"rendered":"Astellas Doses First Patient in Phase 3 Trial of Bispecific ASP2138 for First\u2011Line Gastric Cancer"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Astellas Pharma Inc.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/beta\/quote\/4503:TYO\">TYO: 4503<\/a>) announced that the first patient has been dosed in a <strong>Phase 3 study<\/strong> evaluating <strong>ASP2138<\/strong> in combination with <strong>chemotherapy<\/strong> and <strong>pembrolizumab (Keytruda)<\/strong> as a <strong>first\u2011line treatment<\/strong> in adults with <strong>locally advanced unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma<\/strong> whose tumors are <strong>Claudin 18.2 (CLDN18.2)-positive<\/strong> and <strong>HER2-negative<\/strong>. The milestone advances one of Astellas&#8217;s lead bispecific candidates in a molecularly defined gastric cancer population with a growing competitive landscape.<\/p>\n\n\n\n<h2 id=\"h-study-design-snapshot\" class=\"wp-block-heading\">Study Design Snapshot<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Element<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td>Sponsor<\/td><td><strong>Astellas Pharma Inc.<\/strong> (TYO: 4503)<\/td><\/tr><tr><td>Asset<\/td><td><strong>ASP2138<\/strong>, investigational bispecific antibody<\/td><\/tr><tr><td>Phase<\/td><td>Phase 3 (first patient dosed)<\/td><\/tr><tr><td>Regimen<\/td><td>ASP2138 + chemotherapy + <strong>pembrolizumab (Keytruda)<\/strong><\/td><\/tr><tr><td>Setting<\/td><td>First\u2011line, locally advanced unresectable or metastatic<\/td><\/tr><tr><td>Population<\/td><td>Adults with <strong>gastric or gastroesophageal junction (GEJ) adenocarcinoma<\/strong>, <strong>CLDN18.2-positive<\/strong>, <strong>HER2-negative<\/strong><\/td><\/tr><tr><td>Milestone Date<\/td><td>25 Aug 2026<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-drug-profile-amp-mechanism-of-action\" class=\"wp-block-heading\">Drug Profile &amp; Mechanism of Action<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Molecule:<\/strong> ASP2138, an investigational bispecific antibody<\/li>\n\n\n\n<li><strong>Route:<\/strong> Subcutaneous administration, a convenience differentiator versus intravenous formats<\/li>\n\n\n\n<li><strong>Targets:<\/strong> <strong>CLDN18.2<\/strong>, a protein expressed on certain tumor cells, and <strong>CD3<\/strong> on T cells<\/li>\n\n\n\n<li><strong>Mechanism:<\/strong> By binding both targets, ASP2138 brings CD3\u2011positive T cells closer to CLDN18.2\u2011expressing tumor cells and activates their anti\u2011tumor response<\/li>\n\n\n\n<li><strong>Partner Agent:<\/strong> Combined with standard chemotherapy and pembrolizumab (Keytruda), a backbone regimen in first\u2011line gastric\/GEJ cancer<\/li>\n\n\n\n<li><strong>Biomarker Strategy:<\/strong> Restriction to <strong>CLDN18.2-positive, HER2-negative<\/strong> tumors aligns ASP2138 with the precision\u2011oncology segmentation reshaping first\u2011line gastric cancer care<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-clinical-evidence-phase-3-program\" class=\"wp-block-heading\">Clinical Evidence \u2013 Phase 3 Program<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li>The study marks the first patient dosed in Astellas&#8217;s registrational\u2011intent Phase 3 evaluation of ASP2138 in this biomarker\u2011selected first\u2011line setting.<\/li>\n\n\n\n<li>The CLDN18.2-positive, HER2-negative population is clinically distinct from HER2-positive disease, where separate targeted regimens apply, underscoring the trial&#8217;s focus on a defined segment of gastric\/GEJ adenocarcinoma.<\/li>\n\n\n\n<li>Combining a subcutaneous T\u2011cell\u2011engaging bispecific with chemo\u2011immunotherapy aims to improve upon current first\u2011line standards while maintaining manageable administration for patients.<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-market-impact-amp-outlook\" class=\"wp-block-heading\">Market Impact &amp; Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Large First\u2011Line Opportunity:<\/strong> Gastric and GEJ adenocarcinoma remain among the leading causes of cancer mortality globally, and first\u2011line combination regimens anchor both clinical practice and commercial value in this space.<\/li>\n\n\n\n<li><strong>CLDN18.2 as a Hot Target:<\/strong> The CLDN18.2 arena has become one of oncology&#8217;s most contested frontiers, with multiple antibodies, bispecifics, and ADCs in development; biomarker\u2011selected, chemo\u2011immunotherapy\u2011combined data will be key to differentiation.<\/li>\n\n\n\n<li><strong>Subcutaneous Convenience:<\/strong> Subcutaneous dosing could offer a meaningful administration advantage over intravenous competitors in routine clinical practice if efficacy supports it.<\/li>\n\n\n\n<li><strong>Watch Items:<\/strong> Enrollment pace, interim safety and efficacy readouts, and positioning against other CLDN18.2\u2011targeted agents advancing in first\u2011line gastric cancer.<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong> \u2013 This brief is for informational purposes only and does not constitute investment, medical, or regulatory advice. Statements regarding ongoing clinical development and future commercialization are forward\u2011looking and subject to risks and uncertainties; actual results may differ materially. Refer to official announcements from Astellas Pharma and clinical trial registries for authoritative details.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Astellas Pharma Inc. (TYO: 4503) announced that the first patient has been dosed in a&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,11],"tags":[353,16,62,1177],"class_list":["post-76767","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-astellas-pharma","tag-cancer","tag-clinical-trial-approval-initiation","tag-tyo-4503"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v28.3) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Astellas Doses First Patient in Phase 3 Trial of Bispecific ASP2138 for First\u2011Line Gastric Cancer - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Astellas Pharma Inc. (TYO: 4503) announced that the first patient has been dosed in a Phase 3 study evaluating ASP2138 in combination with chemotherapy and pembrolizumab (Keytruda) as a first\u2011line treatment in adults with locally advanced unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors are Claudin 18.2 (CLDN18.2)-positive and HER2-negative. The milestone advances one of Astellas&#039;s lead bispecific candidates in a molecularly defined gastric cancer population with a growing competitive landscape.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=76767\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Astellas Doses First Patient in Phase 3 Trial of Bispecific ASP2138 for First\u2011Line Gastric Cancer\" \/>\n<meta property=\"og:description\" content=\"Astellas Pharma Inc. (TYO: 4503) announced that the first patient has been dosed in a Phase 3 study evaluating ASP2138 in combination with chemotherapy and pembrolizumab (Keytruda) as a first\u2011line treatment in adults with locally advanced unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors are Claudin 18.2 (CLDN18.2)-positive and HER2-negative. The milestone advances one of Astellas&#039;s lead bispecific candidates in a molecularly defined gastric cancer population with a growing competitive landscape.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=76767\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-08-27T04:34:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-08-27T04:34:01+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=76767#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=76767\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Astellas Doses First Patient in Phase 3 Trial of Bispecific ASP2138 for First\u2011Line Gastric Cancer\",\"datePublished\":\"2026-08-27T04:34:00+00:00\",\"dateModified\":\"2026-08-27T04:34:01+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=76767\"},\"wordCount\":493,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Astellas Pharma\",\"Cancer\",\"Clinical trial approval \\\/ initiation\",\"TYO: 4503\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=76767#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=76767\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=76767\",\"name\":\"Astellas Doses First Patient in Phase 3 Trial of Bispecific ASP2138 for First\u2011Line Gastric Cancer - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-08-27T04:34:00+00:00\",\"dateModified\":\"2026-08-27T04:34:01+00:00\",\"description\":\"Astellas Pharma Inc. (TYO: 4503) announced that the first patient has been dosed in a Phase 3 study evaluating ASP2138 in combination with chemotherapy and pembrolizumab (Keytruda) as a first\u2011line treatment in adults with locally advanced unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors are Claudin 18.2 (CLDN18.2)-positive and HER2-negative. The milestone advances one of Astellas's lead bispecific candidates in a molecularly defined gastric cancer population with a growing competitive landscape.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=76767#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=76767\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=76767#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Astellas Doses First Patient in Phase 3 Trial of Bispecific ASP2138 for First\u2011Line Gastric Cancer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Astellas Doses First Patient in Phase 3 Trial of Bispecific ASP2138 for First\u2011Line Gastric Cancer - Insight, China&#039;s Pharmaceutical Industry","description":"Astellas Pharma Inc. (TYO: 4503) announced that the first patient has been dosed in a Phase 3 study evaluating ASP2138 in combination with chemotherapy and pembrolizumab (Keytruda) as a first\u2011line treatment in adults with locally advanced unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors are Claudin 18.2 (CLDN18.2)-positive and HER2-negative. The milestone advances one of Astellas's lead bispecific candidates in a molecularly defined gastric cancer population with a growing competitive landscape.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=76767","og_locale":"en_US","og_type":"article","og_title":"Astellas Doses First Patient in Phase 3 Trial of Bispecific ASP2138 for First\u2011Line Gastric Cancer","og_description":"Astellas Pharma Inc. (TYO: 4503) announced that the first patient has been dosed in a Phase 3 study evaluating ASP2138 in combination with chemotherapy and pembrolizumab (Keytruda) as a first\u2011line treatment in adults with locally advanced unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors are Claudin 18.2 (CLDN18.2)-positive and HER2-negative. The milestone advances one of Astellas's lead bispecific candidates in a molecularly defined gastric cancer population with a growing competitive landscape.","og_url":"https:\/\/flcube.com\/?p=76767","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-08-27T04:34:00+00:00","article_modified_time":"2026-08-27T04:34:01+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=76767#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=76767"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Astellas Doses First Patient in Phase 3 Trial of Bispecific ASP2138 for First\u2011Line Gastric Cancer","datePublished":"2026-08-27T04:34:00+00:00","dateModified":"2026-08-27T04:34:01+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=76767"},"wordCount":493,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Astellas Pharma","Cancer","Clinical trial approval \/ initiation","TYO: 4503"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=76767#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=76767","url":"https:\/\/flcube.com\/?p=76767","name":"Astellas Doses First Patient in Phase 3 Trial of Bispecific ASP2138 for First\u2011Line Gastric Cancer - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-08-27T04:34:00+00:00","dateModified":"2026-08-27T04:34:01+00:00","description":"Astellas Pharma Inc. (TYO: 4503) announced that the first patient has been dosed in a Phase 3 study evaluating ASP2138 in combination with chemotherapy and pembrolizumab (Keytruda) as a first\u2011line treatment in adults with locally advanced unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors are Claudin 18.2 (CLDN18.2)-positive and HER2-negative. The milestone advances one of Astellas's lead bispecific candidates in a molecularly defined gastric cancer population with a growing competitive landscape.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=76767#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=76767"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=76767#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Astellas Doses First Patient in Phase 3 Trial of Bispecific ASP2138 for First\u2011Line Gastric Cancer"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"","_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/76767","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=76767"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/76767\/revisions"}],"predecessor-version":[{"id":76769,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/76767\/revisions\/76769"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=76767"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=76767"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=76767"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}